Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, reviews developments in 2017 for the treatment of lung cancer.
Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, reviews developments in 2017 for the treatment of lung cancer.
According to Brahmer, 2017 has been an amazing year of changes in non-small cell lung cancer (NSCLC). For example, there has been improvement in progression-free survival (PFS) for patients with stage III disease treated with durvalumab (Imfinzi) after chemotherapy and radiation therapy. Additionally, changes in metastatic disease with chemotherapy combinations are showing an advantage compared to chemotherapy alone.
IMpower data investigating bevacizumab (Avastin) with paclitaxel/carboplatin and atezolizumab (Tecentriq) has demonstrated an improvement in PFSbut choosing the right patients is important, explains Brahmer. Adding bevacizumab to chemotherapy improves overall survival (OS) and response rate, but adding atezolizumab creates even more advantages from an immune standpoint.
In data from KEYNOTE-021 cohort G, pembrolizumab (Keytruda) in combination with pemetrexed and carboplatin increased response rate and PFS. OS data needs to mature.
In 2018, Brahmer is excited to see OS data from first-line phase III trials.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More